|
| 通痹汤对气虚痰瘀互结证稳定型心绞痛患者的临床观察 |
| Clinical Observation of Tongbi Decoction on Stable Angina Pectoris of Qi Deficiency and Phlegm Stasis Syndrome |
| 投稿时间：2022-12-23 录用日期：2023-02-01 |
| DOI： |
| 中文关键词: 通痹汤 稳定型心绞痛 sLOX-1 PDH |
| 英文关键词: Tongbi Decoction Stable angina pectoris sLOX-1 PDH |
| 基金项目:上海市嘉定区卫计委课题(2020-KY-ZYY-04) |
|
| 摘要点击次数: 44 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：观察通痹汤对气虚痰瘀互结证稳定型心绞痛患者的疗效及对sLOX-1水平和PDH活性的影响。方法：选取符合纳入标准的稳定型心绞痛患者102例，采用随机、对照方法进行分组，每组34例。基础组给予心绞痛常规治疗，治疗组予基础组联合中药口服，对照组予基础组联合盐酸曲美他嗪缓释片口服，观察比较三组治疗前及治疗12周后临床疗效、中医证候积分、高敏肌钙蛋白I（hs-cTnI）、血凝素样氧化低密度脂蛋白受体-1（sLOX-1）、丙酮酸脱氢酶（PDH）变化情况。结果：治疗后，治疗组总有效率91.18%(31/34)，优于对照组79.41%(27/34)和基础组61.76%(21/34)（P＜0.05）；治疗后，治疗组、对照组hs-cTnI下降优于基础组（P＜0.01），治疗组与对照组比较无统计学意义（P＞0.05）；三组治疗后治疗组、对照组较基础组PDH活性有所升高（P＜0.01），且治疗组患者PDH活性高于对照组（P＜0.05）；三组治疗后治疗组sLOX-1明显低于对照组和基础组 (P＜0.01)。结论：通痹汤改善心绞痛患者临床疗效优于曲美他嗪，其作用机制可能与减少冠状动脉脂质堆积、血清炎症反应，改善心肌细胞葡萄糖有氧代谢，减轻心肌缺氧损伤有关。 |
| 英文摘要: |
| oboective: To observe the therapeutic effect of Tongbi decoction on stable angina pectoris patients with qi deficiency phlegm blood stasis syndrome and its effect on sLOX-1 level and PDH activity. Methods：102 patients with stable angina pectoris who met the inclusion criteria were randomly divided into 34 patients in each group. The basic group was given routine treatment for angina pectoris, the treatment group was given the basic group combined with traditional Chinese medicine orally, and the control group was given the basic group combined with trimetazidine hydrochloride sustained-release tablets orally. The clinical efficacy, TCM syndrome score, high-sensitivity troponin I (hs-cTnI), oxidized low-density lipoprotein receptor 1 (sLOX-1), and pyruvate dehydrogenase (PDH) changes of the three groups were compared after 12 weeks of treatment. Results ：After treatment, the total effective rate of the treatment group was 91.18% (31/34), which was better than 79.41% (27/34) of the control group and 61.76% (21/34) of the basic group (P＜0.05); After treatment, the levels of hs-cTnI in the treatment group and the control group were better than the basic group (P＜0.01)，and there was no significance between the treatment group and the control group (P＞0.05); After treatment, the PDH activity in the treatment group and control group was higher than that in the basic group (P＜0.01), and the PDH activity in the treatment group was higher than that in the control group (P＜0.05); After treatment, sLOX-1 in the treatment group was significantly lower than those in the three groups (P＜0.01). Conclusion: Tongbi decoction is superior to trimetazidine in improving the clinical efficacy of patients with angina pectoris. Its mechanism may be related to reducing coronary artery lipid accumulation, serum inflammatory reaction, improving the aerobic metabolism of glucose in myocardial cells, and alleviating myocardial hypoxia injury. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
